Graham CN, Borker R, Oppe M, Uyl-de Groot CA, Brogan AJ, Barber B. Cost-effectiveness of panitumumab plus best supportive care (BSC) compared with BSC alone in chemorefractory metastatic colorectal cancer (MCRC) patients (PTS) with wild-type (WT) KRAS tumor status in the Netherlands. Poster presented at the 33rd European Society for Medical Oncology (ESMO) Congress; September 2008.